Paxista is an investigational antiviral therapy medicine with active ingredients Nirmatrelvir 150 MG and Ritonavir 100 MG approved for emergency use. The drug is indicated for treating mild-to-moderate coronavirus disease in adults and pediatric patients (aged >12 years and weight>40 kg) testing positive for SARS-CoV-2 virus, at high risk of progression, including hospitalization or death.

Ritonavir is co-administered with Nirmatrelvir as it acts as a pharmacokinetic enhancer resulting in higher systemic concentrations and a longer half-life of Nirmatrelvir, thereby supporting a twice-daily administration regimen

Uses of Paxista:

Paxista is approved for emergency use in treating both high-risk adults and pediatric patients (aged >12 years and weight>40 kg) who are diagnosed with mild to moderate COVID 19 positive confirmed cases.

Paxista - Paxlovid medicine reduces the risk of hospitalization or mortality rate.

Paxista is not approved for use in

·         pediatric patients younger than 12 years of age or weighing less than 40 kg.
·         pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

·         For initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19.